PRESS RELEASE

Q2 2024 — Press release

Q2 2024PDF · 13 pages294 KB
Confidential
News Release
____________________________________________________________________________
Merck Announces Second-Quarter 2024 Financial Results
- 	Total Worldwide Sales Were $16.1 Billion, an Increase of 7% From Second Quarter
2023; Excluding the Impact of Foreign Exchange, Growth Was 11%
- 	KEYTRUDA Sales Grew 16% to $7.3 Billion; Excluding the Impact of Foreign Exchange,
Sales Grew 21%
- 	GAAP EPS Was $2.14; Non-GAAP EPS Was $2.28
- 	Successful Initial Launch of WINREVAIR in the U.S.; Received Positive EU CHMP
Opinion for Adults With PAH
- 	Achieved Key Milestones in Vaccine Programs
o 	Following FDA Approval, CAPVAXIVE Unanimously Recommended by the
CDC’s ACIP for Pneumococcal Vaccination for Certain Adults
o 	Announced Positive Results From Phase 2b/3 Trial of Clesrovimab (MK-1654),
an Investigational RSV Preventative Monoclonal Antibody for Infants
- 	Completed Acquisitions of EyeBio and Elanco’s Aqua Business in July 2024
- 	Full-Year 2024 Financial Outlook
o 	Raises and Narrows Expected Worldwide Sales Range To Be Between $63.4
Billion and $64.4 Billion
o 	Now Expects Non-GAAP EPS To Be Between $7.94 and $8.04; Outlook Reflects
Negative Impact From One-Time Charge of Approximately $1.3 Billion, or $0.51
per Share, for the Acquisition of EyeBio
RAHWAY, N.J., July 30, 2024 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the second quarter of 2024.
“Our business is demonstrating strong momentum as we exit the first half of the year,”
said Robert M. Davis, chairman and chief executive officer, Merck. “Through excellent scientific,
commercial and operational execution, we’re achieving significant milestones for our company
and for patients, including the launch of WINREVAIR. I am proud of our dedicated teams around
the world that are working tirelessly to advance our deep pipeline as we continue delivering
innovation that solves unmet medical needs.”

-- 1 of 13 --

- 2 -
Confidential
Financial Summary
$ in millions, except EPS amounts
Second Quarter
2024 	2023 	Change
Change Ex-
Exchange
Sales 	$16,112 	$15,035 	7% 	11%
GAAP net income (loss)1 	5,455 	(5,975) 	N/M 	N/M
Non-GAAP net income (loss) that excludes certain items 1,2* 	5,809 	(5,220) 	N/M 	N/M
GAAP EPS 	2.14 	(2.35) 	N/M 	N/M
Non-GAAP EPS that excludes certain items 2* 	2.28 	(2.06) 	N/M 	N/M
*Refer to table on page 7.
N/M – Not meaningful
For the second quarter of 2024, Generally Accepted Accounting Principles (GAAP)
earnings per share (EPS) assuming dilution was $2.14 and non-GAAP EPS was $2.28. GAAP
and non-GAAP loss per share for the second quarter of 2023 include a charge of $4.02 per
share for the acquisition of Prometheus Biosciences, Inc. (Prometheus). Non-GAAP EPS in
both periods excludes acquisition- and divestiture-related costs, costs related to restructuring
programs, as well as income and losses from investments in equity securities. Non-GAAP EPS
in the second quarter of 2024 also excludes a tax benefit due to a reduction in reserves for
unrecognized income tax benefits, resulting from the expiration of the statute of limitations for
assessments related to the 2019 federal tax return year.
Year-to-date results can be found in the attached tables.
1 Net income (loss) attributable to Merck & Co., Inc.
2 Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but
not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.

-- 2 of 13 --

- 3 -
Confidential
Second-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Second Quarter
$ in millions 	2024 	2023 	Change
Change
Ex-
Exchange 	Commentary
Total Sales 	$16,112 	$15,035 	7% 	11%
Approximately 2 percentage points of the
negative impact of foreign exchange was due
to devaluation of Argentine peso, which was
largely offset by inflation-related price
increases, consistent with practice in that
market.
Pharmaceutical 	14,408 	13,457 	7% 	11%
Increase driven by growth in oncology,
cardiovascular and vaccines, partially offset by
declines in diabetes and virology.
KEYTRUDA 	7,270 	6,271 	16% 	21%
Growth driven by increased global uptake in
earlier-stage indications, including triple-
negative breast cancer (TNBC) and renal cell
carcinoma, as well as non-small cell lung
cancer in the U.S., and continued strong global
demand from metastatic indications.
Approximately 4 percentage points of the
negative impact of foreign exchange was due
to devaluation of Argentine peso, which was
largely offset by inflation-related price
increases.
GARDASIL/
GARDASIL 9 	2,478 	2,458 	1% 	4%
Growth primarily due to higher sales in the
U.S. driven by higher pricing, demand and
public-sector buying patterns, as well as higher
demand in certain ex-U.S. markets. Growth
was largely offset by lower sales in China due
to timing of shipments compared with prior
year.
JANUVIA/JANUMET 	629 	864 	-27% 	-23%
Decline primarily due to lower pricing and
demand in the U.S., as well as ongoing
generic competition in many international
markets, particularly in Europe and the Asia
Pacific region.
PROQUAD, M-M-R II
and VARIVAX 	617 	582 	6% 	7%
Growth largely from higher pricing and
demand in the U.S.
BRIDION 	455 	502 	-9% 	-8%
Decline primarily due to generic competition in
certain ex-U.S. markets, particularly in Europe
and the Asia Pacific region, partially offset by
higher demand in the U.S.
Lynparza* 	317 	310 	2% 	4%
Growth due to higher demand in the U.S. and
certain international markets, particularly in
China and Europe.
Lenvima* 	249 	242 	3% 	4%
Growth primarily from higher demand in the
U.S.
VAXNEUVANCE 	189 	168 	13% 	16%
Growth largely driven by continued uptake
from launches in Japan and Europe, partially
offset by lower demand and public-sector
buying patterns in the U.S.
PREVYMIS 	188 	143 	31% 	35%
Growth primarily due to higher global demand,
particularly in the U.S., China and Europe.

-- 3 of 13 --

- 4 -
Confidential
ROTATEQ 	163 	131 	25% 	26%
Growth primarily due to timing of shipments to
China and public-sector buying patterns in the
U.S., partially offset by lower demand in the
U.S.
WELIREG 	126 	50 	150% 	150%
Growth primarily driven by higher demand in
the U.S., largely attributable to launch of a new
indication.
LAGEVRIO 	110 	203 	-46% 	-42%
Decline due to lower demand and pricing in
certain markets in the Asia Pacific region,
partially offset by higher demand in Japan and
the U.S.
WINREVAIR 	70 	- 	- 	-
Represents sales in the U.S. following
approval in March 2024. About 40% of sales
were attributable to doses administered to
patients and remainder was due to distributors
building inventory in support of increasing
demand.
Animal Health 	1,482 	1,456 	2% 	6%
Growth primarily driven by higher pricing in
both Livestock and Companion Animal product
portfolios, as well as higher demand for
Livestock products, partially offset by a decline
in Companion Animal distributor inventory.
Approximately 3 percentage points of the
negative impact of foreign exchange was due
to devaluation of Argentine peso, which was
largely offset by inflation-related price
increases.
Livestock 	837 	807 	4% 	11%
Growth primarily driven by higher demand for
ruminant and poultry products, as well as
higher pricing across product portfolio.
Companion Animal 	645 	649 	-1% 	1%
Sales were relatively flat compared with prior
year reflecting lower distributor inventory,
largely offset by higher pricing across product
portfolio. Sales of BRAVECTO were $331
million and $326 million in current and prior-
year quarters, respectively, which represented
growth of 2%, or 3% excluding impact of
foreign exchange.
Other Revenues** 	222 	122 	82% 	53%
Growth primarily due to higher royalty income
and favorable impact of revenue hedging
activities.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue hedging activities.

-- 4 of 13 --

- 5 -
Confidential
Second-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Second Quarter 2024
Cost of sales 	$3,745 	$606 	$66 	$- 	$3,073
Selling, general and administrative 	2,739 	24 	31 	- 	2,684
Research and development 	3,500 	20 	- 	- 	3,480
Restructuring costs 	80 	- 	80 	- 	-
Other (income) expense, net 	42 	(17) 	- 	(49) 	108
Second Quarter 2023
Cost of sales 	$4,024 	$467 	$32 	$- 	$3,525
Selling, general and administrative 	2,702 	25 	52 	- 	2,625
Research and development 	13,321 	9 	1 	- 	13,311
Restructuring costs 	151 	- 	151 	- 	-
Other (income) expense, net 	172 	(3) 	- 	194 	(19)
GAAP Expense, EPS and Related Information
Gross margin was 76.8% for the second quarter of 2024 compared with 73.2% for the
second quarter of 2023. The increase was primarily due to the favorable impact of product mix
(including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), partially
offset by higher amortization of intangible assets.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the second
quarter of 2024, an increase of 1% compared with the second quarter of 2023. The increase
was primarily due to higher administrative and promotional costs, largely offset by the favorable
impact of foreign exchange and lower restructuring costs.
Research and development (R&D) expenses were $3.5 billion in the second quarter of
2024 compared with $13.3 billion in the second quarter of 2023. The decrease was primarily
due to a $10.2 billion charge in the second quarter of 2023 for the acquisition of Prometheus,
partially offset by higher clinical development spending and increased compensation and benefit
costs.
Other (income) expense, net, was $42 million of expense in the second quarter of 2024
compared with $172 million of expense in the second quarter of 2023. The decrease was
primarily due to income from investments in equity securities in 2024 compared with losses in
2023, partially offset by higher net interest expense in 2024.
3 Reflects expenses related to acquisitions of businesses, including the amortization of intangible assets, intangible asset
impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 5 of 13 --

- 6 -
Confidential
The effective tax rate of 9.1% for the second quarter of 2024 includes a 4.3 percentage
point favorable impact due to a reduction in reserves for unrecognized income tax benefits,
resulting from the expiration of the statute of limitations for assessments related to the 2019
federal tax return year.
GAAP EPS was $2.14 for the second quarter of 2024 compared with GAAP loss per
share of $2.35 for the second quarter of 2023. GAAP loss per share in the second quarter of
2023 includes a charge of $4.02 per share for the acquisition of Prometheus.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 80.9% for the second quarter of 2024 compared with
76.6% for the second quarter of 2023. The increase was primarily due to the favorable impact of
product mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9).
Non-GAAP SG&A expenses were $2.7 billion in the second quarter of 2024, an increase
of 2% compared with the second quarter of 2023. The increase was primarily due to higher
administrative and promotional costs, largely offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $3.5 billion in the second quarter of 2024 compared
with $13.3 billion in the second quarter of 2023. The decrease was primarily due to a $10.2
billion charge in the second quarter of 2023 for the acquisition of Prometheus, partially offset by
higher clinical development spending and increased compensation and benefit costs.
Non-GAAP other (income) expense, net, was $108 million of expense in the second
quarter of 2024 compared with $19 million of income in the second quarter of 2023, primarily
due to higher net interest expense.
The non-GAAP effective tax rate was 14.1% for the second quarter of 2024.
Non-GAAP EPS was $2.28 for the second quarter of 2024 compared with non-GAAP
loss per share of $2.06 for the second quarter of 2023. Non-GAAP loss per share in the second
quarter of 2023 includes a charge of $4.02 per share for the acquisition of Prometheus.

-- 6 of 13 --

- 7 -
Confidential
A reconciliation of GAAP to non-GAAP net income (loss) and EPS is provided in the
table that follows.
Pipeline and Portfolio Highlights
In the second quarter, Merck demonstrated further progress in its strong and diverse
pipeline, achieving multiple regulatory and clinical milestones.
In vaccines, Merck recently received approval from the U.S. Food and Drug
Administration (FDA) for CAPVAXIVE, now the first pneumococcal conjugate vaccine
specifically designed to address the serotypes responsible for approximately 85% of invasive
pneumococcal disease cases in adults age 65 and older, based on the U.S. Centers for Disease
Control and Prevention (CDC) data from 2018-2021. The CDC’s Advisory Committee on
Immunization Practices (ACIP) unanimously voted to recommend CAPVAXIVE for adults age
65 and older who have not received a pneumococcal conjugate vaccine or whose vaccination
history is unknown, for adults 19 to 64 with certain risk conditions, and for adults 19 and older
who have started their pneumococcal vaccine series with PCV13. Additionally, shared clinical
decision-making is recommended for a supplemental dose of CAPVAXIVE for adults over 65
who completed their vaccine series with both PCV13 and PPSV23.
The company also recently announced positive topline results from its Phase 2b/3 trial of
clesrovimab (MK-1654), an investigational respiratory syncytial virus (RSV) preventative
monoclonal antibody for infants, which met all primary safety and efficacy endpoints.
In cardiometabolic disease, Merck continued to make progress in its launch of
WINREVAIR in the U.S. As of the end of June, more than 1,000 patients have received
WINREVAIR. The company also announced that the European Union’s (EU) Committee for
4 Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments, as well as a $259 million benefit in the second quarter of 2024, due to a reduction in reserves for
unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019
federal tax return year.
Second Quarter
$ in millions, except EPS amounts 	2024 	2023
EPS
GAAP EPS 	$2.14 	$(2.35)
Difference 	0.14 	0.29
Non-GAAP EPS that excludes items listed below2 	$2.28 	$(2.06)
Net Income (Loss)
GAAP net income (loss)1 	$5,455 	$(5,975)
Difference 	354 	755
Non-GAAP net income (loss) that excludes items listed below1,2 	$5,809 	$(5,220)
Excluded Items:
Acquisition- and divestiture-related costs3 	$633 	$498
Restructuring costs 	177 	236
(Income) loss from investments in equity securities 	(49) 	194
Decrease to net income/increase to net loss before taxes 	761 	928
Income tax (benefit) expense4 	(407) 	(173)
Decrease to net income/increase to net loss 	$354 	$755

-- 7 of 13 --

- 8 -
Confidential
Medicinal Products for Human Use (CHMP) issued a positive opinion for WINREVAIR. If
approved by the European Commission, WINREVAIR will be the first activin signaling inhibitor
therapy for pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1)
to be approved in Europe, offering a new treatment option for certain adults with this rare,
progressive disease. Additional worldwide regulatory filings for WINREVAIR are underway.
In oncology, Merck received FDA approval for KEYTRUDA in combination with
chemotherapy, followed by KEYTRUDA as a single agent, for the treatment of certain patients
with endometrial carcinoma. This marks the 40th indication for KEYTRUDA in the U.S.,
reinforcing its importance as a foundational therapy for certain types of cancer.
At the 2024 American Society of Clinical Oncology Annual Meeting, new data were
presented on four approved oncology medicines and four pipeline candidates in more than 25
types of cancer. In collaboration with Moderna, Inc., Merck announced encouraging three-year
follow-up data for V940 (mRNA-4157) in combination with KEYTRUDA for the adjuvant
treatment of patients with high-risk stage III and IV melanoma following complete resection. In
addition, new Phase 3 data from a study conducted in China and independently led by Kelun-
Biotech evaluating sacituzumab tirumotecan (MK-2870/SKB264), an investigational anti-TROP2
antibody-drug conjugate being developed by Merck in collaboration with Kelun-Biotech, were
presented in previously treated patients with locally recurrent or metastatic TNBC.
Merck Animal Health launched the 12-month injectable formulation of BRAVECTO for
use in dogs in a number of markets in Europe for the treatment and persistent killing of fleas
(Ctenocephalides felis and Ctenocephalides canis) and ticks (Rhipicephalus sanguineus, Ixodes
ricinus, Ixodes hexagonus, and Dermacentor reticulatus). In addition, in July 2024, Merck
completed the acquisition of the aqua business of Elanco Animal Health Incorporated.
In July 2024, Merck also completed the acquisition of Eyebiotech Limited (EyeBio),
which includes the lead candidate Restoret™/MK-3000 that is being evaluated for the treatment
of patients with certain retinal diseases, including diabetic macular edema and neovascular age-
related macular degeneration, as well as preclinical candidates. And, Merck and Orion
Corporation announced the mutual exercise of an option to convert the companies’ ongoing co-
development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an
investigational CYP11A1 inhibitor, and other candidates, into an exclusive global license for
Merck.

-- 8 of 13 --

- 9 -
Confidential
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Approved KEYTRUDA Plus Carboplatin and Paclitaxel as
Treatment for Adult Patients With Primary Advanced or Recurrent
Endometrial Carcinoma, Based on Results From Phase 3 NRG-
GY018/KEYNOTE-868 Trial
(Read Announcement)
FDA Granted Priority Review to Merck’s Application for KEYTRUDA
Plus Chemotherapy as First-Line Treatment of Patients With
Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma,
Based on Results From Phase 3 KEYNOTE-483 Trial; FDA Set
Prescription Drug User Fee Act (PDUFA) Date of Sept. 25, 2024
(Read Announcement)
Merck Received Positive EU CHMP Opinion for KEYTRUDA Plus
Padcev as First-Line Treatment for Patients With Unresectable or
Metastatic Urothelial Carcinoma, Based on Results From Phase 3
KEYNOTE-A39/EV-302 Trial
(Read Announcement)
Moderna and Merck Announced Three-Year Data for mRNA-4157
(V940) in Combination With KEYTRUDA Demonstrated Sustained
Improvement in Recurrence-Free Survival and Distant Metastasis-Free
Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV
Melanoma Following Complete Resection
(Read Announcement)
Merck Announced Phase 3 KEYNOTE-522 Trial Met Its Overall
Survival (OS) Endpoint in Patients With High-Risk Early-Stage TNBC (Read Announcement)
Merck Announced Phase 3 KEYNOTE-811 Trial Met Dual Primary
Endpoint of OS as First-Line Treatment in Patients With HER2-Positive
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
(Read Announcement)
Patritumab Deruxtecan Biologics License Application Submission
Received Complete Response Letter From FDA Due to Inspection
Findings at Third-Party Manufacturer
(Read Announcement)
Vaccines
FDA Approved CAPVAXIVE for Prevention of Invasive Pneumococcal
Disease and Pneumococcal Pneumonia in Adults, Based on Results
From Four Phase 3 Trials
(Read Announcement)
CDC’s ACIP Unanimously Recommended CAPVAXIVE for
Pneumococcal Vaccination in Appropriate Adults (Read Announcement)
Merck Announced Topline Results From Phase 2b/3 Trial of
Clesrovimab (MK-1654), an Investigational RSV Preventative
Monoclonal Antibody for Infants, Met All Primary Safety and Efficacy
Endpoints
(Read Announcement)
Cardiometabolic Merck Received Positive EU CHMP Opinion for WINREVAIR
(sotatercept) in PAH (Read Announcement)

-- 9 of 13 --

- 10 -
Confidential
Full-Year 2024 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2024
Updated 	Prior
Sales * 	$63.4 to $64.4 billion 	$63.1 to $64.3 billion
Non-GAAP Gross margin 2 	Approximately 81% 	Approximately 81%
Non-GAAP Operating expenses 2** 	$26.8 to $27.6 billion 	$25.2 to $26.1 billion
Non-GAAP Other (income) expense, net 2 	Approximately $350 million expense 	Approximately $250 million expense
Non-GAAP Effective tax rate2 	15.5% to 16.5% 	14.5% to 15.5%
Non-GAAP EPS2*** 	$7.94 to $8.04 	$8.53 to $8.65
Share count (assuming dilution) 	Approximately 2.54 billion 	Approximately 2.55 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $656 million for Harpoon Therapeutics, Inc. (Harpoon) acquisition and $1.3 billion for EyeBio
acquisition. Outlook does not assume any additional significant potential business development transactions.
***Includes one-time charges totaling $0.77 per share for the Harpoon and EyeBio acquisitions.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and gains and losses from investments
in equity securities either owned directly or through ownership interests in investment funds,
without unreasonable effort. These items are inherently difficult to forecast and could have a
significant impact on the company’s future GAAP results.
Merck continues to experience strong global demand for key growth products,
particularly in oncology, and despite impacts related to the lower sell out of GARDASIL from
Zhifei Biological Products Co., Ltd. (the company’s distributor and commercialization partner in
China) into the points of vaccination in the market during the quarter, Merck is raising and
narrowing its full-year sales outlook.
Merck now expects its full-year sales to be between $63.4 billion and $64.4 billion,
including a negative impact of foreign exchange of approximately 3 percentage points, at mid-
July 2024 exchange rates. Approximately 2 percentage points of the negative impact of foreign
exchange is due to the devaluation of the Argentine peso, which the company expects will
largely be offset by inflation-related price increases, consistent with practice in that market.
Merck now expects its full-year non-GAAP effective income tax rate to be between
15.5% and 16.5%, which includes an unfavorable impact related to the one-time charge for the
acquisition of EyeBio, which is not tax deductible.
Merck now expects its full-year non-GAAP EPS to be between $7.94 and $8.04,
including one-time charges of $0.26 and $0.51 per share for the acquisitions of Harpoon and
EyeBio, respectively. The outlook includes a negative impact of foreign exchange of more than
$0.30 per share. The negative impact of foreign exchange is primarily due to the devaluation of

-- 10 of 13 --

- 11 -
Confidential
the Argentine peso, which the company expects will largely be offset by inflation-related price
increases, consistent with practice in that market. This revised non-GAAP EPS range reflects
the following items, which were not previously included in the outlook:
• 	A charge of $1.3 billion, or $0.51 per share, for the acquisition of EyeBio.
• 	Estimated 2024 expense of approximately $0.09 per share to be incurred to finance the
EyeBio and Elanco aqua business acquisitions and to advance the acquired assets.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, income and losses from investments in equity securities, as well as a
tax benefit in 2024 due to a reduction in reserves for unrecognized income tax benefits,
resulting from the expiration of the statute of limitations for assessments related to the 2019
federal tax return year.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Tuesday, July 30, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (800) 779-0641 (U.S. and Canada Toll-Free)
or (517) 308-9147 and using the access code 4761229.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and

-- 11 of 13 --

- 12 -
Confidential
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
VARIVAX (Varicella Virus Vaccine Live)

-- 12 of 13 --

- 13 -
Confidential
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 13 of 13 --